OBJECTIVE: To investigate the effects of rosiglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the secretion of vascular endothelial growth factor (VEGF) by peripheral blood mononuclear cells (PBMCs) and on the generation of reactive oxygen species (ROS) by leukocytes. METHODS: PBMCs and leukocytes were obtained from venous blood samples collected from 20 healthy individuals. VEGF secretion was evaluated using a commercial ELISA kit, while ROS production was determined using a luminol-dependent chemiluminescence assay. RESULTS: Rosiglitazone and calphostin C (a protein kinase C inhibitor) inhibited VEGF secretion by PBMCs by 63.7 and 62.3%, respectively. Both agents reduced ROS production in non-stimulated human leukocytes and down-regulated the enhanced generation of ROS in leukocytes that had been stimulated with the PKC activator phorbol 12,13-dibutyrate. CONCLUSION: The results support the involvement of PKC as a direct, and/or NADPH-oxidase as an indirect, target for the action of rosiglitazone on VEGF secretion by PBMCs and ROS production in human leukocytes.
OBJECTIVE: To investigate the effects of rosiglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the secretion of vascular endothelial growth factor (VEGF) by peripheral blood mononuclear cells (PBMCs) and on the generation of reactive oxygen species (ROS) by leukocytes. METHODS: PBMCs and leukocytes were obtained from venous blood samples collected from 20 healthy individuals. VEGF secretion was evaluated using a commercial ELISA kit, while ROS production was determined using a luminol-dependent chemiluminescence assay. RESULTS:Rosiglitazone and calphostin C (a protein kinase C inhibitor) inhibited VEGF secretion by PBMCs by 63.7 and 62.3%, respectively. Both agents reduced ROS production in non-stimulated human leukocytes and down-regulated the enhanced generation of ROS in leukocytes that had been stimulated with the PKC activator phorbol12,13-dibutyrate. CONCLUSION: The results support the involvement of PKC as a direct, and/or NADPH-oxidase as an indirect, target for the action of rosiglitazone on VEGF secretion by PBMCs and ROS production in human leukocytes.
Authors: Hyo Jung Kim; Im Sun Woo; Eun Sil Kang; So Young Eun; Gil Hyeong Kim; Sun Ah Ham; Hye Jung Kim; Jae Heun Lee; Ki Churl Chang; Jin-Hoi Kim; Hoon Taek Lee; Han Geuk Seo Journal: Biochem Biophys Res Commun Date: 2006-08-23 Impact factor: 3.575
Authors: Masuko Ushio-Fukai; Yan Tang; Tohru Fukai; Sergey I Dikalov; Yuxian Ma; Mitsuaki Fujimoto; Mark T Quinn; Patrick J Pagano; Chad Johnson; R Wayne Alexander Journal: Circ Res Date: 2002-12-13 Impact factor: 17.367
Authors: Karsten Grote; Inna Flach; Maren Luchtefeld; Elvan Akin; Steven M Holland; Helmut Drexler; Bernhard Schieffer Journal: Circ Res Date: 2003-05-15 Impact factor: 17.367
Authors: Minako Yamaoka-Tojo; Masuko Ushio-Fukai; Lula Hilenski; Sergey I Dikalov; Yuqing E Chen; Taiki Tojo; Tohru Fukai; Mitsuaki Fujimoto; Nikolay A Patrushev; Ningning Wang; Christopher D Kontos; George S Bloom; R Wayne Alexander Journal: Circ Res Date: 2004-06-24 Impact factor: 17.367
Authors: Wei-Chun J Hsu; Norelle C Wildburger; Sigmund J Haidacher; Miroslav N Nenov; Oluwarotimi Folorunso; Aditya K Singh; Brent C Chesson; Whitney F Franklin; Ibdanelo Cortez; Rovshan G Sadygov; Kelly T Dineley; Jay S Rudra; Giulio Taglialatela; Cheryl F Lichti; Larry Denner; Fernanda Laezza Journal: Exp Neurol Date: 2017-05-15 Impact factor: 5.330